These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4054194)

  • 41. Plasma levels and beta-blocking effect of alpha-hydroxymetoprolol--metabolite of metoprolol--in the dog.
    Regårdh CG; Ek L; Hoffmann KJ
    J Pharmacokinet Biopharm; 1979 Oct; 7(5):471-9. PubMed ID: 43384
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol.
    Leemann TD; Devi KP; Dayer P
    Eur J Clin Pharmacol; 1993; 45(1):65-71. PubMed ID: 8405032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol.
    Floras JS; Jones JV; Hassan MO; Sleight P
    Br Med J (Clin Res Ed); 1982 Nov; 285(6352):1387-92. PubMed ID: 6814568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.
    Dayer P; Leemann T; Marmy A; Rosenthaler J
    Eur J Clin Pharmacol; 1985; 28(2):149-53. PubMed ID: 2859203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.
    Plosker GL; Clissold SP
    Drugs; 1992 Mar; 43(3):382-414. PubMed ID: 1374320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.
    Lewis RV; Lennard MS; Jackson PR; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1985 Mar; 19(3):329-33. PubMed ID: 2859048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metoprolol oxidation by rat liver microsomes. Inhibition by debrisoquine and other drugs.
    Lennard MS; Crewe HK; Tucker GT; Woods HF
    Biochem Pharmacol; 1986 Aug; 35(16):2757-61. PubMed ID: 2943287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.
    Leemann T; Dayer P; Meyer UA
    Eur J Clin Pharmacol; 1986; 29(6):739-41. PubMed ID: 3709620
    [No Abstract]   [Full Text] [Related]  

  • 53. Relative activities of atenolol and metoprolol on the cardiovascular system of man.
    Harry JD; Cruickshank JM; Young J; Barker N
    Eur J Clin Pharmacol; 1981; 20(1):9-15. PubMed ID: 7308277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
    Bozkurt A; Basçi NE; Işimer A; Sayal A; Kayaalp SO
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
    Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
    Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
    Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects.
    Murthy SS; Nelson WL; Shen DD; Power JM; Cahill CM; McLean AJ
    Drug Metab Dispos; 1991; 19(6):1093-100. PubMed ID: 1687016
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol.
    Blomqvist I; Westergren G; Sandberg A; Jonsson UE; Lundborg P
    Eur J Clin Pharmacol; 1988; 33 Suppl():S19-24. PubMed ID: 3371390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.
    Mikus G; Gross AS; Beckmann J; Hertrampf R; Gundert-Remy U; Eichelbaum M
    Clin Pharmacol Ther; 1989 May; 45(5):562-7. PubMed ID: 2498026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations.
    Sohn DR; Kusaka M; Shin SG; Jang IJ; Chiba K; Ishizaki T
    Ther Drug Monit; 1992 Jun; 14(3):184-9. PubMed ID: 1412602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.